Epinastine hydrobromide is a histamine H1 receptor antagonist used for the treatment of allergic rhinitis, urticaria, eczema, dermatitis, pruritus, prurigo, ordinary psoriasis with pruritus, and allergic bronchial asthma in adults. It is characterized by high efficacy, excellent safety profile, broad therapeutic indications, minimal drug interactions, and low cardiotoxicity. Clinical studies have demonstrated that epinastine exhibits superior therapeutic efficacy compared to other second-generation H1 antagonists such as terfenadine, astemizole, and ketotifen at equivalent doses, with a lower incidence of central sedative effects and cardiotoxicity.